Biotech News
Related news
INABIN8bio2026-08-06 20:01 EST
IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights
INABIN8bio2026-08-10 20:01 EST
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NRIXNurix Therapeutics2026-08-20 11:00 EST
Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer
REGNRegeneron Pharmaceuticals2026-06-25 20:05 EST
Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast
ERASErasca2026-08-10 12:00 EST
Erasca Strengthens R&D Leadership with Appointment of Internationally Recognized Medical Oncologist Charles S. Fuchs, M.D., M.P.H., as President of R&D
GERNGeron2026-07-13 12:00 EST
Geron Announces Appointment of Chinmaya Rath as Chief Business Officer
BNTXBioNTech2026-08-03 09:00 EST
BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer
REPLReplimune Group2026-07-30 22:15 EST
Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma
SNDXSyndax Pharmaceuticals2026-07-28 11:00 EST
Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026
CGEMCullinan Therapeutics, Inc.2026-07-28 11:00 EST
Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML
IN8bio
Gamma-Delta T-Cell Therapies IN8bio develops gamma-delta T-cell therapies and T-cell engagers for cancer and autoimmune disease. The platform seeks to use the innate and adaptive properties of gamma-delta T cells to recognize stressed or malignant cells. Glioblastoma Program The company's clinical work in glioblastoma evaluates...
Recent company news
INABIN8bio2026-08-10 20:01 EST
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
INABIN8bio2026-08-06 20:01 EST
IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights
INABIN8bio2026-07-09 12:00 EST
IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma
INABIN8bio2026-06-03 12:30 EST
IN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination Therapies
INABIN8bio2026-06-01 12:30 EST
IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026
Stock data
- Close
- 1.28 USD
- Market cap
- 14.96M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States